Vadadustat
「Vadadustat」熱門搜尋資訊
「Vadadustat」文章包含有：「FDA拒絕批准貧血藥物Vadadustat，Akebia大規模裁員」、「《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒！...」、「《腎臟病》慢性腎病貧血候選藥物vadadustat意外落馬」、「《FDA》安全問題!美國FDA拒絕批准Akebia慢性腎病貧血藥...」、「Vafseo」、「Vafseo,INN-vadadustat」、「VadadustatinPatientswithAnemiaandNon–Dialysis」、「FDAProvidesAkebiaTherapeuticsaPathForwardfor...」、「Afterhigh」、「Erythropo...
查看更多
FDA 拒絕批准貧血藥物Vadadustat，Akebia 大規模裁員
https://geneonline.news
美國食品藥物管理局（FDA）因為安全問題近期拒絕批准美國生物製藥公司Akebia Therapeutics 用於治療慢性腎病引起的貧血藥物Vadadustat，因其增加了血栓
《FDA》不服慢性腎病貧血藥物Vadadustat藥證申請遭拒！ ...
http://www.genetinfo.com
Vadadustat為一種口服缺氧誘導因子脯氨醯羥化酶抑制劑(HIF-PHI)，旨在模擬人體對於低水平氧氣的反應，透過抑制HIF-PH可以促進紅血球增生並改善向組織的 ...
《腎臟病》慢性腎病貧血候選藥物vadadustat 意外落馬
http://www.genetinfo.com
今年3 月30 日，美國FDA 以安全性問題，拒絕批准Akebia Therapeutics 原被相當被看好、用於治療慢性腎病貧血的低氧誘導因子脯胺醯羥化酶(HIF-PH) 抑制 ...
《FDA》安全問題! 美國FDA 拒絕批准Akebia 慢性腎病貧血藥 ...
http://www.genetinfo.com
據了解，在該試驗中，雖然使用vadadustat 的患者比使用對比藥物的患者出現了更多的血栓栓塞事件，但總體事件發生率是相同的─ 都是6.6 人/100 患者年( ...
Vafseo
https://www.ema.europa.eu
The active substance in Vafseo, vadadustat, acts on an enzyme called hypoxia-inducible factor prolyl hydroxylase (HIF-PH). This stimulates the natural response ...
Vafseo, INN-vadadustat
https://www.ema.europa.eu
Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease. (CKD) in adults on chronic maintenance dialysis. Page 3. 3.
Vadadustat in Patients with Anemia and Non–Dialysis
https://www.nejm.org
Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate ...
FDA Provides Akebia Therapeutics a Path Forward for ...
https://ir.akebia.com
Vadadustat is approved in Europe for the treatment of symptomatic anemia due to CKD in adult patients on chronic maintenance dialysis. In Japan ...
After high
https://www.fiercepharma.com
Akebia plans to resubmit its application for vadadustat for anemia due to chronic kidney disease in adult patients on dialysis by the end of the ...
Erythropoietic effects of vadadustat in patients with anemia ...
https://pubmed.ncbi.nlm.nih.go
Thus, overall, vadadustat had beneficial effects on three aspects of erythropoiesis in patients with anemia associated with CKD: increased endogenous EPO ...